MedTrace Logo

PEG-interferon Alfa-2a add-on Study in HBeAg Negative Chronic Hepatitis B Patients

NCT01373684 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2019-11-08

No results posted yet for this study

Summary

This study intends to investigate whether addition of PEG-IFN alfa-2a in HBeAg-negative chronic hepatitis B patients who are pretreated with nucleos(t)ide analogues enhances the degree of HBsAg decline.

Conditions

Interventions

DRUG

Peginterferon alfa-2a

180 μg per week s.c. for a total duration of 48 weeks.

DRUG

Nucleos(t)ide analogue

All patients are all currently being treated with long-term NA treatment and will continue using these during the study. Dosage depends on which Nucleos(t)ide analogue they are using.

Sponsors & Collaborators

Principal Investigators

  • H.L.A. Janssen, MD PhD · Erasmus Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-05-25
Primary Completion
2019-10-28
Completion
2019-10-28

Countries

  • Canada
  • Netherlands

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01373684 on ClinicalTrials.gov